Siliq is made by Valeant Pharmaceuticals International, Inc who is a multinational specialty pharmaceutical company.
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.
In February 2017, it had received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.
Siliq is a brand-name prescription medication.
The drug Siliq is also used to treat moderate to severe plaque psoriasis in adults.
Plaque psoriasis is one of many kinds of psoriasis.
Siliq is a systemic treatment, which means it works throughout your body.
The standard retail cost of Siliq without health insurance is $5,985.07 per 2, 1.5ML of 210MG/1.5ML Syringe though you can save using a SingleCare Siliq coupon to pay only $5,206.15 for 2, 1.5ml of 210mg/1.5ml Syringe of Siliq.
People without access to insurance can still use SingleCare for free Siliq coupons.
Siliq (brodalumab) is approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis.
The recommended dosage of Siliq to treat plaque psoriasis is 210 mg.
For your first three weeks of treatment with Siliq, you'll receive a dose of 210 mg once per week.
Then, after your first 3 weeks have been completed, you will only need to inject a dose of 210 mg of Siliq once every 2 weeks.
SILIQ is intended for use under the guidance and supervision of a healthcare professional.
Patients may self-inject SILIQ when deemed appropriate by a healthcare professional and after proper training in subcutaneous injection technique using the prefilled syringe.